Tourmaline Bio Inc
NASDAQ:TRML
Intrinsic Value
Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of TRML.
Tourmaline Bio Inc's market capitalization is 609.2m USD.
TRML stock price is 15.25 USD.
TRML.
TRML. Open DCF Valuation
TRML. Open Relative Valuation
TRML has upside potential of 290% compared to the average analyst price target.
Open Wall St Estimates
TRML has negative Free Cash Flow for the last twelve months.
TRML's ROE (Return on Equity) has decreased in the last 3 years from -19% to -22%, and is approaching profitability.
TRML has negative Operating Income for the last twelve months.
TRML has negative Net Income for the last twelve months.
TRML's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -668% to -615%, and is approaching profitability.
TRML's ROE (Return on Equity) for the past 12 months is negative and is equal to -22%.
TRML's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -615%.
TRML has negative three-year average ROE (Return on Equity): -26%. The company is not efficient at transforming stockholders' equity into net income.
TRML has negative three-year average ROIC (Return on Invested Capital): -789%. The company is not efficient at using invested capital to generate operating income.
TRML's short-term assets (209m USD) exceed its short-term liabilties (5m USD).
TRML's long-term assets (210m USD) exceed its long-term liabilties (5m USD).
TRML's D/E (Debt to Equity) is very low and is equal to 0.
TRML's Altman Z-Score is very high and is equal to 118.33.
Fundamental Analysis
Tourmaline Bio Inc
Balance Sheet Decomposition
Tourmaline Bio Inc
| Current Assets | 208.9m |
| Cash & Short-Term Investments | 203m |
| Other Current Assets | 5.9m |
| Non-Current Assets | 1.4m |
| PP&E | 570k |
| Other Non-Current Assets | 851k |
| Current Liabilities | 5m |
| Accounts Payable | 1.1m |
| Accrued Liabilities | 3.9m |
| Non-Current Liabilities | 251k |
| Other Non-Current Liabilities | 251k |
Earnings Waterfall
Tourmaline Bio Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-45.4m
USD
|
|
Operating Income
|
-45.4m
USD
|
|
Other Expenses
|
3.3m
USD
|
|
Net Income
|
-42.1m
USD
|
Free Cash Flow Analysis
Tourmaline Bio Inc
TRML Profitability Score
Profitability Due Diligence
Tourmaline Bio Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Tourmaline Bio Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
TRML Solvency Score
Solvency Due Diligence
Tourmaline Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Tourmaline Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRML Price Targets Summary
Tourmaline Bio Inc
According to Wall Street analysts, the average 1-year price target for
TRML
is 59.5 USD
with a low forecast of 48.48 USD and a high forecast of 77.7 USD.
Ownership
TRML Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
TRML Price
Tourmaline Bio Inc
| Average Annual Return | -45.76% |
| Standard Deviation of Annual Returns | 67.41% |
| Max Drawdown | -95% |
| Market Capitalization | 609.2m USD |
| Shares Outstanding | 39 946 135 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Tourmaline Bio Inc
Country
Industry
Market Cap
Dividend Yield
Description
Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Louisville, Kentucky and currently employs 129 full-time employees. The company went IPO on 2021-05-07. Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The firm is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The firm focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.
You don't have any saved screeners yet
